Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.81 |
| ▸ | GAA | P10253 | 5/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.81 |
| ▸ | TOP2A | P11388 | 5/20 | 0.81 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.81 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.81 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.81 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12308351 | 1.00 | CYP3A4 (0.81) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL16606226 | 1.00 | CYP3A4 (0.81) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL15060571 | 1.00 | CYP3A4 (0.81) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL422175 | 0.94 | CYP3A4 (0.89) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL17816434 | 0.94 | CYP3A4 (0.89) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL19959379 | 0.94 | CYP3A4 (0.89) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL15472841 | 0.94 | CYP3A4 (0.89) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL13818627 | 0.94 | CYP3A4 (0.89) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL10061877 | 0.94 | CYP3A4 (0.89) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL24482748 | 0.89 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120058112-A1 | ANTIBODIES | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
| US-20110262525-A1 | METHODS OF TREATMENT | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | MERCK SHARP & DOHME CORP. | 2011-04-21 | — | — | US | disclosed |
| US-20110014117-A1 | ANTI-IGF1R | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | VEGFA, KDR, FLT4 | CYP3A4 4812/4885GAA 1902/4885SMN1; SMN2 4415/4885 |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | IGF1R, IRS1, EWSR1 | CYP3A4 2778/4885GAA 242/4885SMN1; SMN2 1667/4885 |
| US-20110014117-A1 | ANTI-IGF1R | IGF1R, IGFBP1, IGFBP2 | CYP3A4 4884/4885GAA 221/4885SMN1; SMN2 2621/4885 |
| US-20120058112-A1 | ANTIBODIES | IGF1R, EGFR, ERBB3 | CYP3A4 4577/4885GAA 2191/4885SMN1; SMN2 1795/4885 |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | TERF2IP, TERF2, DOT1L | CYP3A4 4781/4885GAA 4123/4885SMN1; SMN2 3879/4885 |
| US-20110262525-A1 | METHODS OF TREATMENT | ASAH2, FOLH1, CD44 | CYP3A4 4405/4885GAA 410/4885SMN1; SMN2 818/4885 |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | IGF1R, IGFBP1, IGFBP2 | CYP3A4 4849/4885GAA 1418/4885SMN1; SMN2 2063/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | CYP3A4 3752/4885GAA 695/4885SMN1; SMN2 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.